AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06314711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: High-frequency ultrasound of ex vivo specimen
Study NCT06437301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline measure of ETCO2 without mask
Description: Baseline
Study NCT06437301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline ETCO2 with mask
Description: Mask
Study NCT06437301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ETCO2 after 200 meter walk with mask
Description: 200 meter walk and mask
Study NCT06437301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ETCO2 after 200 meter walk without mask
Description: 200 meter walk
Study NCT06262152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy, blood and salivary sample, and sleep evaluation
Description: * For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment.~* 7 days actigraph recording through wearing of Actiwatch spectrum plus at home~* Standardized sleep questionnaire administration
Study NCT05441384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)
Description: 7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
Study NCT06577363 — intervention group
Intervention type: DRUG
Intervention: Maribavir
Description: Maribavir tablets
Study NCT05816811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power-focused resistance training
Description: Participants will undergo 10 weeks of power-focused resistance training.
Study NCT05454033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal
Study NCT05454033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal
Study NCT05454033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No-treatment control
Study NCT04912583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High tidal volume
Description: A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
Study NCT04912583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low tidal volume
Description: A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
Study NCT06546163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline survey
Description: Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
Study NCT06546163 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Baseline survey
Description: Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
Study NCT06546163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Participants randomized to the intervention arm will receive a standardized HRV sensor and accompanying smartphone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be asked to practice their HRVB skills at home for 10 minutes for two weeks.
Study NCT06546163 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Participants randomized to the waitlist control arm will receive educational materials on eating disorders and stress management and will be sent home with these materials after completing the baseline survey. They will be encouraged to read the materials over the next two weeks before coming in for T2 survey.
Study NCT05123872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
Study NCT06379789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGV131
Description: Single dose administered via intravenous (IV) infusion before LNP1265
Study NCT06116955 — intervention group
Intervention type: DRUG
Intervention: Midazolam and sufentanil
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
Study NCT06116955 — intervention group
Intervention type: DRUG
Intervention: Midazolam, sufentanil and propofol
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
Study NCT06379789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP1265
Description: Single dose administered via IV infusion following REGV131
Study NCT00588926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
Study NCT05062655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug reconciliation
Description: Drug reconciliation information transmission to pharmacist interview with the patient
Study NCT06276062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal radius fracture fixation in pediatrics.
Description: using double short titanium elastic nails in treatment of pediatric distal radius fractures.
Study NCT05403996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activa-Mente
Description: Active break program
Study NCT06177977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SS-HH-OCT
Description: The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
Study NCT05252546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib tablet
Description: single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
Study NCT05252546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montmorillonite Power
Description: 3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
Study NCT05252546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
Study NCT06116955 — intervention group
Intervention type: DRUG
Intervention: Remazolam and sufentanil.
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
Study NCT06116955 — intervention group
Intervention type: DRUG
Intervention: Remazolam, sufentanil and propofol
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
Study NCT05110872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette flavor restricted and e-cigarette flavor restricted
Description: 1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace
Study NCT05110872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette flavor restricted and e-cigarette flavor unrestricted
Description: 1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace
Study NCT05110872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette flavor unrestricted and e-cigarette flavor restricted
Description: 1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace
Study NCT05110872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette flavor unrestricted and e-cigarette flavor unrestricted
Description: 1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace
Study NCT04090918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac examination programme 3 months after abdominal surgery
Description: Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
Study NCT05400291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chondroitin Sulfate Staining
Description: Staining of histopathological slides
Study NCT06269224 — intervention group
Intervention type: OTHER
Intervention: Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.
Description: The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
Study NCT06026384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text in non-narrative form
Description: Participants will be asked to read a text and give feedback afterwards
Study NCT06026384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text in narrative form
Description: Participants will be asked to read a text and give feedback afterwards
Study NCT06026384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animated video in non-narrative form
Description: Participants will be asked to watch a video and give feedback afterwards
Study NCT06026384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animated video in narrative form
Description: Participants will be asked to watch a video and give feedback afterwards
Study NCT05588336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
Study NCT06266481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical dexamethasone
Description: Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
Study NCT06266481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% lidocaine was sprayed over the tube for the second group
Description: Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
Study NCT05487612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Invasive Extracorporeal Circulation
Description: Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
Study NCT05487612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiopulmonary bypass
Description: Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
Study NCT05280340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
Study NCT05324293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-115
Description: Once Every 2 weeks, subcutaneously injection
Study NCT06384079 — intervention group
Intervention type: PROCEDURE
Intervention: Antegrade and retrograde pyelogram
Description: Participation in the study will guarantee that participants will receive this procedure.
Study NCT05656859 — intervention group
Intervention type: BEHAVIORAL
Intervention: Single group
Description: Survey
Study NCT04997486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
Study NCT06002620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB+
Description: standard care
Study NCT06002620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched nutrition food (CEF)
Description: enriched cricket flour at 20%
Study NCT06002620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: regular videos, sms reminders and face to face interaction
Study NCT06002620 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined nutrition and education
Description: combined enriched cricket flour and nutrition education
Study NCT06002412 — intervention group
Intervention type: OTHER
Intervention: Image quality control
Description: The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
Study NCT04997317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
Description: 177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
Study NCT04997317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
Description: 177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
Study NCT04997317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTA-JR11 (Phase I/II)
Description: In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
Study NCT05638256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
Study NCT05009875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food SBD111
Description: Two capsules administered twice daily with morning and evening meals for 52 weeks
Study NCT05009875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules administered twice daily with morning and evening meals for 52 weeks
Study NCT06533475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minzasolmin tablet formulation under fasting condition
Description: Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
Study NCT06533475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minzasolmin Granules in capsule under fasting condition
Description: Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition
Study NCT06533475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minzasolmin tablet formulation under fed condition
Description: Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition
Study NCT06179199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOOMA™ tDCS™
Description: The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
Study NCT06179199 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SOOMA™ tDCS™
Description: The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
Study NCT05133297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose1 BID daily for 24 weeks.
Study NCT05133297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose2 BID daily for 24 weeks.
Study NCT05133297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered at dose3 BID daily for 24 weeks.
Study NCT05133297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral tablets administered at 5 mg BID daily for 24 weeks.
Study NCT04762511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lower dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study NCT04762511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study NCT04641377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention plus health education
Description: The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
Study NCT04641377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
Study NCT04762511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study NCT04762511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose formulation of HSV vaccine (GSK4108771A)
Description: 2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study NCT04762511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.